Why Hims & Hers Health Stock Just Crashed

Hims & Hers missed Q1 expectations badly, posting a loss of $0.40 per share versus $0.01 expected and revenue of $608 million versus $616.5 million expected. Sales grew just 4% despite 9% subscriber growth, while the stock fell 12% intraday. Offsetting the miss, management raised full-year sales guidance to $2.8 billion-$3.0 billion and said free cash flow was positive at $53 million for the quarter.

Analysis

The market is likely treating this as an execution miss, but the deeper issue is unit economics: subscriber growth is no longer converting into revenue at the same rate, which suggests mix dilution, lower monetization per user, or promotional intensity rising to defend growth. That matters more than the headline EPS miss because it implies the business is becoming more dependent on volume expansion just as competition in consumer telehealth is intensifying and customer acquisition costs may be re-accelerating.

The strategic pivot toward branded GLP-1 resale is the important second-order signal. It reduces litigation overhang versus compounded alternatives, but it also compresses margin optionality and makes the company more like a distribution layer than a differentiated platform; over time, that shifts bargaining power back toward manufacturers like LLY and NVO. In other words, the safer product strategy may improve durability but likely lowers long-run gross margin ceiling and weakens the narrative that HIMS can own the category.

Guidance is the only near-term support for the stock, but the path to that range now depends on a sharp inflection in monetization rather than just user adds. If the next 1-2 quarters show revenue per subscriber stabilizing, the drawdown can reverse quickly because sentiment is positioned for a slowdown; if not, the market will re-rate the name as a low-quality growth story with headline FCF but limited earnings power. The key catalyst window is the next earnings print and any legal/regulatory noise around GLP-1 sourcing, where downside can remain fast and reflexive.

The contrarian view is that the selloff may be too focused on the EPS miss and not enough on the company’s ability to keep free cash flow positive while de-risking the most contested product line. If management can prove branded GLP-1 replaces lost compounded demand without a major margin collapse, the stock could stabilize well before GAAP profitability arrives. But absent evidence of pricing power, the current guidance looks more like aspiration than proof.

Key Decisions for Investors

• Short HIMS on strength over the next 1-3 sessions; target a retracement toward the pre-earnings range if the market fades the guidance beat, with a hard stop above any post-print gap fill that reclaims momentum.
• Prefer a pair trade: long LLY or NVO vs short HIMS over the next 1-2 quarters, expressing the view that branded GLP-1 economics accrue to manufacturers while HIMS absorbs lower-margin distribution risk. Risk/reward improves if regulatory scrutiny around telehealth remains elevated.
• Sell downside volatility via HIMS put spreads for the next earnings cycle only if the stock fully stabilizes first; the thesis is that the name is now event-driven, so premium is attractive, but naked short gamma is dangerous given headline sensitivity.
• Watch for a better entry in HIMS only after one quarter of revenue-per-subscriber stabilization; until then, treat any bounce as lower-quality and vulnerable to another de-rating.
• If you want exposure to consumer healthcare growth, allocate to LLY/NVO instead of HIMS; they capture the economic rent from GLP-1 expansion with materially lower litigation and execution risk.